ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31
Zomedica Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.08−0.00 (-0.55%)
Close on Oct 19, 2026
- Market cap
- $77.40M
- P/E (TTM)
- –
- Dividend yield
- –
Zomedica statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Zomedica | Industry median |
|---|---|---|
| Market Cap | $77.40M | $164.85M |
| Enterprise Value | $70.20M | $87.06M |
| PS Ratio | 2.10 | 3.60 |
| PB Ratio | 0.72 | 2.03 |
| P/TBV Ratio | 1.11 | 2.31 |
Enterprise value
| Measure | Zomedica | Industry median |
|---|---|---|
| EV / Sales | 1.90 | 2.43 |
Income (trailing twelve months)
| Measure | Zomedica | Industry median |
|---|---|---|
| Revenue | $36.88M | $57.94M |
| Gross Profit | $24.13M | $90.47M |
| Operating Income | -$20.75M | -$21.44M |
| Pretax Income | -$19.12M | -$14.45M |
| Net Income | -$18.95M | -$22.46M |
| EBITDA | -$20.75M | -$16.91M |
| EPS (Diluted) | -$0.01 | -$0.83 |
Margins
| Measure | Zomedica | Industry median |
|---|---|---|
| Gross Margin | 65.4% | 52.3% |
| Operating Margin | -56.3% | -44.5% |
| Pretax Margin | -51.8% | -13.0% |
| Profit Margin | -51.4% | -39.2% |
| EBITDA Margin | -56.3% | -31.3% |
| FCF Margin | -37.1% | -8.85% |
Returns
| Measure | Zomedica | Industry median |
|---|---|---|
| Return on Equity (ROE) | -16.3% | -53.1% |
| Return on Assets (ROA) | -14.9% | -41.0% |
| Return on Invested Capital (ROIC) | -15.1% | -32.0% |
| Return on Capital Employed (ROCE) | -19.0% | -37.8% |
Growth
| Measure | Zomedica | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 30.1% | 6.01% |
| Revenue Growth (3Y CAGR) | 19.2% | 2.25% |
Balance sheet
| Measure | Zomedica | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $7.19M | $62.42M |
| Net Cash (Debt) | $7.19M | $15.68M |
| Net Cash Per Share | $0.01 | $0.66 |
| Equity (Book Value) | $107.28M | $48.79M |
| Book Value Per Share | $0.11 | $1.36 |
| Tangible Book Value | $69.92M | $23.06M |
| Working Capital | $48.89M | $75.77M |
Financial position
| Measure | Zomedica | Industry median |
|---|---|---|
| Current Ratio | 6.43 | 3.30 |
| Quick Ratio | 1.43 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Zomedica | Industry median |
|---|---|---|
| Operating Cash Flow | -$13.37M | -$12.35M |
| Capital Expenditures | -$302.00K | -$1.06M |
| Free Cash Flow | -$13.67M | -$20.28M |
| FCF Per Share | -$0.01 | -$0.42 |
Efficiency
| Measure | Zomedica | Industry median |
|---|---|---|
| Asset Turnover | 0.29 | 0.38 |
| Inventory Turnover | 2.17 | 2.67 |
| Revenue Per Employee | $261.54K | $398.96K |
| Profits Per Employee | -$134.40K | -$703.34K |
| Employee Count | 141 | 74 |
Dividends and yields
| Measure | Zomedica | Industry median |
|---|---|---|
| Earnings Yield | -24.5% | -22.7% |
| FCF Yield | -17.7% | -9.07% |
Shares
| Measure | Zomedica | Industry median |
|---|---|---|
| Shares Outstanding | 979,950,000 | 58,179,650 |
| Shares Change (YoY) | 0.00% | 11.1% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 952,661,000 | 49,173,100 |
| Shares Held by Insiders | 2.78% | 11.6% |
| Shares Held by Institutions | 0.01% | 59.4% |
Taxes
| Measure | Zomedica | Industry median |
|---|---|---|
| Income Tax | -$168.00K | $91.50K |
Scores
| Measure | Zomedica | Industry median |
|---|---|---|
| Altman Z-Score | 0.85 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Zomedica's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.